INT210065

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2007
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 8
Total Number 16
Disease Relevance 6.45
Pain Relevance 0.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (SH3GL3) endosome (SH3GL3) signal transduction (SH3GL3)
cytoplasm (SH3GL3)
Anatomy Link Frequency
plasma 3
endothelium 2
urine 2
epithelial cells 1
podocytes 1
SH3GL3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain score 24 97.60 Very High Very High Very High
ischemia 14 96.36 Very High Very High Very High
Pain 79 95.92 Very High Very High Very High
Paracetamol 10 92.44 High High
fibrosis 54 86.48 High High
Central nervous system 50 82.72 Quite High
corticosteroid 5 75.68 Quite High
Antihistamine 5 74.92 Quite High
cva 30 58.32 Quite High
carbamazepine 5 34.32 Quite Low
Disease Link Frequency Relevance Heat
Disease 299 99.24 Very High Very High Very High
Fabry Disease 526 98.40 Very High Very High Very High
Pain 103 97.32 Very High Very High Very High
Proteinuria 786 96.88 Very High Very High Very High
Fever 27 96.60 Very High Very High Very High
Cv Unclassified Under Development 14 96.36 Very High Very High Very High
Chills 4 96.20 Very High Very High Very High
Angiokeratoma 43 94.60 High High
Stress 9 87.92 High High
Renal Disease 401 87.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ERT resulted in decreased plasma and urine GL-3 levels even after a short-term treatment, and reduced GL-3 accumulation in various organs and tissues (24).
Positive_regulation (accumulation) of GL-3 in urine
1) Confidence 0.45 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.34 Pain Relevance 0
The clinical efficacy of ERT was associated with stabilization of renal function, a significant reduction in the GL-3 level, and improvement in renal pathology (34).
Positive_regulation (stabilization) of GL-3
2) Confidence 0.34 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.64 Pain Relevance 0.15
In summary, this study demonstrates that the clinical effects of ERT were associated with a significant reduction in the serum and urine GL-3 levels, and clearance of the accumulated GL-3 from the vascular endothelium of biopsied kidney.
Positive_regulation (accumulated) of GL-3 in urine
3) Confidence 0.32 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.30 Pain Relevance 0.17
All patients exhibited increased plasma GL-3 levels, except for two female heterozygotes.
Neg (except) Positive_regulation (increased) of GL-3 in plasma
4) Confidence 0.30 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.78 Pain Relevance 0
ERT was shown to reduce GL-3 accumulation in dermal endothelium in children with Fabry disease (Wraith et al 2008).
Positive_regulation (accumulation) of GL-3 in endothelium associated with fabry disease
5) Confidence 0.16 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.56 Pain Relevance 0.04
More information is needed about the relationship between the total accumulation of GL-3 and the burden of disease in the individual patient.
Positive_regulation (accumulation) of GL-3 associated with disease
6) Confidence 0.16 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.33 Pain Relevance 0
ERT resulted in decreased plasma and urine GL-3 levels even after a short-term treatment, and reduced GL-3 accumulation in various organs and tissues (24).
Positive_regulation (accumulation) of GL-3 in plasma
7) Confidence 0.15 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.34 Pain Relevance 0
The increase in urinary GL-3 excretion above baseline in antibody-positive patients treated with ERT at 0.2 mg/kg every other week only became apparent after 6 months of infusion therapy, was not correlated with infusion-related reactions.
Positive_regulation (increase) of GL-3
8) Confidence 0.13 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0 Pain Relevance 0
The glomerular epithelial cells still contain lamellar inclusions; these are minimally cleared of GL-3 even after extended course of ERT (Germain et al 2007).
Positive_regulation (cleared) of GL-3 in epithelial cells
9) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.25 Pain Relevance 0
Six of the other 9 active treatment group patients showed substantial but not complete improvement in their GL-3 accumulation scores.
Positive_regulation (accumulation) of GL-3
10) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.19 Pain Relevance 0.08
Males have higher plasma and urinary levels of GL-3 than females, and the plasma and urinary GL-3 levels correlate with each other, however, there is not correlation between elevated GL-3 levels and clinical symptoms (Vedder et al 2007).
Positive_regulation (elevated) of GL-3 in plasma
11) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.36 Pain Relevance 0
The overall composite score for microvascular endothelial GL-3 accumulation decreased from 4.9 ± 1.5 at baseline to 0.7 ± 0.8 at week 20 (85.7% decrease).
Positive_regulation (accumulation) of GL-3
12) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.10 Pain Relevance 0.10
In all patients, light and electron microscopy showed severe GL-3 accumulation in podocytes.
Positive_regulation (accumulation) of GL-3 in podocytes
13) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.40 Pain Relevance 0
With time, progressive GL-3 accumulation in the microvasculature and parenchyma leads to microvascular dysfunction, occlusion, and ischemia.
Positive_regulation (accumulation) of GL-3 in parenchyma associated with ischemia
14) Confidence 0.11 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 1.07 Pain Relevance 0.14
The first placebo controlled trial with agalsidase beta focused mainly on surrogate endpoints, including clearance of GL-3 from renal endothelium as well as a reduction in GL-3 accumulation in the heart, skin and plasma [6].
Positive_regulation (accumulation) of GL-3 in endothelium
15) Confidence 0.05 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.50 Pain Relevance 0.17
All but two females in the agalsidase beta group had elevated urinary GL-3 levels (>400 nmol/24 h) at baseline.
Positive_regulation (elevated) of GL-3
16) Confidence 0.04 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.30 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox